Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: J Mult Scler (Foster City). 2014 Dec 11;2(1):1000131. doi: 10.4172/2376-0389.1000131

Figure 2.

Figure 2

The in vivo efficacies of PLP-B7AP and controls in suppressing EAE in the mouse model determined by (A) clinical disease score and (B) percent change in body weight, relative to day 8 (day of disease onset). PBS-treated mice received s.c. injections of 100 µl of PBS on days 4, 7, and 10. PLP-, B7AP-, PLP + B7AP mixture-, and PLP-B7AP-treated mice received 100 nmol/100 µl in PBS on days 4, 7, and 10 (s.c.). Results are expressed as the mean clinical score ± SEM (n = 8 for PLP-B7AP and n = 6 for all others).